ATE279446T1 - Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen - Google Patents

Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen

Info

Publication number
ATE279446T1
ATE279446T1 AT00922751T AT00922751T ATE279446T1 AT E279446 T1 ATE279446 T1 AT E279446T1 AT 00922751 T AT00922751 T AT 00922751T AT 00922751 T AT00922751 T AT 00922751T AT E279446 T1 ATE279446 T1 AT E279446T1
Authority
AT
Austria
Prior art keywords
dissolving
production
hydrophobic compounds
structured systems
amphiphilic cyclodextrins
Prior art date
Application number
AT00922751T
Other languages
German (de)
English (en)
Inventor
Rachel Auzely-Velty
Bruno Perly
Florence Djedaini-Pilard
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of ATE279446T1 publication Critical patent/ATE279446T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
AT00922751T 1999-04-29 2000-04-26 Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen ATE279446T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9905460A FR2792942B1 (fr) 1999-04-29 1999-04-29 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
PCT/FR2000/001102 WO2000066635A1 (fr) 1999-04-29 2000-04-26 Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes

Publications (1)

Publication Number Publication Date
ATE279446T1 true ATE279446T1 (de) 2004-10-15

Family

ID=9545038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922751T ATE279446T1 (de) 1999-04-29 2000-04-26 Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen

Country Status (7)

Country Link
US (1) US6858723B1 (enExample)
EP (1) EP1177217B1 (enExample)
JP (1) JP4698842B2 (enExample)
AT (1) ATE279446T1 (enExample)
DE (1) DE60014885T2 (enExample)
FR (1) FR2792942B1 (enExample)
WO (1) WO2000066635A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022100A1 (en) * 2002-08-15 2004-03-18 Yunqing Liu Soild nano pharmaceutical formulation and preparation method thereof
KR20140070676A (ko) * 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
FR2850972B1 (fr) * 2003-02-07 2005-03-11 Commissariat Energie Atomique Derives de per(3,6-anhydro) cyclodextrines, leur preparation et leur utilisation pour vehiculer des elements metalliques vers des cibles biologiques ou pour decontaminer des cibles ou fluides biologiques
FR2861396B1 (fr) * 2003-10-24 2005-12-16 Commissariat Energie Atomique Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations
CN1894283B (zh) * 2003-12-18 2012-07-04 西巴特殊化学品控股有限公司 反应性多糖衍生物、其制备及其用途
EP1735326A4 (en) * 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals BETA-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST LETHAL ANTHRAX TOXIN
CN101151037A (zh) * 2005-01-28 2008-03-26 平纳克尔医药股份有限公司 作为抗菌剂的β-环糊精衍生物
EP2023896B8 (en) * 2006-05-19 2016-09-14 Viroblock SA A composition for inactivating an enveloped virus
FR2907455A1 (fr) * 2006-10-18 2008-04-25 Commissariat Energie Atomique Oligosaccharides cycliques,notamment derives de cyclodextrines amphiphiles,substitues par un ou plusieurs groupements polycycles naturels,tels que les triterpenoides.
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
FR2919872B1 (fr) * 2007-08-10 2009-12-18 Commissariat Energie Atomique Derives de cyclodextrines
JP5364923B2 (ja) * 2009-01-28 2013-12-11 学校法人福岡大学 多機能性シクロデキストリン誘導体、その包接化合物およびそれらの製造方法。
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9051479B2 (en) * 2012-10-12 2015-06-09 Empire Technology Development Llc Paints and coatings containing cyclodextrin additives
CN105392804B (zh) * 2013-08-09 2018-07-10 生物辐射实验室股份有限公司 采用修饰的环糊精的蛋白质检测
TW202009013A (zh) * 2018-08-14 2020-03-01 優你康光學股份有限公司 具有功能性成分的隱形眼鏡及其產品
US20220362401A1 (en) * 2019-09-20 2022-11-17 The University Of Kitakyushu Particles, method for producing particles, drug, method for producing drug, and anti-cancer agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681868A1 (fr) * 1991-09-30 1993-04-02 Sederma Sa Nouvelles substances amphiphiles derivees de cyclodextrines et leur utilisation dans des compositions cosmetiques.
FR2726765B1 (fr) 1994-11-14 1996-12-20 Cis Bio Int Compositions radiopharmaceutiques comprenant un complexe d'inclusion d'une cyclodextrine et d'un acide gras radiohalogene
FR2736056B1 (fr) * 1995-06-29 1997-08-08 Commissariat Energie Atomique Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises
WO2002055562A2 (en) * 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials

Also Published As

Publication number Publication date
JP4698842B2 (ja) 2011-06-08
EP1177217B1 (fr) 2004-10-13
JP2002543249A (ja) 2002-12-17
EP1177217A1 (fr) 2002-02-06
DE60014885D1 (de) 2004-11-18
FR2792942B1 (fr) 2001-06-08
FR2792942A1 (fr) 2000-11-03
DE60014885T2 (de) 2005-10-27
WO2000066635A1 (fr) 2000-11-09
US6858723B1 (en) 2005-02-22

Similar Documents

Publication Publication Date Title
DE60014885D1 (de) Amphiphile cyclodextrine, deren herstellung und verwendung zur auflösung von strukturierten systemen und zur einbettung von hydrophoben verbindungen
Zia et al. Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE) 7M-β-CD to HP-β-CD
Qiu et al. Spiropyran-linked dipeptide forms supramolecular hydrogel with dual responses to light and to ligand–receptor interaction
Montenegro et al. Idebenone: novel strategies to improve its systemic and local efficacy
KR960700074A (ko) 고용해성다성분봉입체착화합물(Highy soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin)
Ahmed et al. Polyphosphates as inhibitors for poly (vinyl chloride) photodegradation
DE60225571D1 (de) Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen
CY1106890T1 (el) Παραγωγα της ακριδινης και η χρηση τους ως φαρμακων
Cannavà et al. Phase solubility and FTIR-ATR studies of idebenone/sulfobutyl ether β-cyclodextrin inclusion complex
ES2119496T3 (es) Composicion de polvo de polimero redispersable que contiene ciclodextrinas o derivados de ciclodextrina.
ATE214290T1 (de) Cyclodextrine zur reduzierung des durch zytotoxische substanzen verursachten gefässaustritts
Ji et al. Regulating Higher‐Order Organization through the Synergy of Two Self‐Sorted Assemblies
Piel et al. Development of a non-surfactant parenteral formulation of miconazole by the use of cyclodextrins
Al-Heibshy et al. Preparation and in vitro characterization of rosuvastatin calcium incorporated methyl beta cyclodextrin and Captisol® inclusion complexes
HUP9701945A1 (hu) Ciklodextrint és taxánszármazékot tartalmazó injekciós gyógyszerkészítmény
BRPI0116332B8 (pt) “método para aumentar a estabilidade de uma composição farmacêutica compreendendo cetotifeno, processo para produção da dita composição e uso de um recipiente de pe”
BRPI0503828A (pt) formulações contendo pó, aquosas, lìquidas, não alcoólicas
DE69728783D1 (de) Verbesserte arzneimittel
BR9909189A (pt) Suspensão de agente ativo peroral
ATE151763T1 (de) Taxolderivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
Pilipović et al. Cyclodextrins, surfactants and their inclusion complexes
EP0788373B1 (en) Novel complexes of taxol or taxotere and pharmaceutical compositions
Blaj et al. Enrofloxacin Pharmaceutical Formulations through the Polymer-Free Electrospinning of β-Cyclodextrin–oligolactide Derivatives
Ol’khovich et al. Inclusion complexes of hydroxypropyl-β-cyclodextrin with novel cytotoxic compounds: Solubility and thermodynamic properties
Shehatta Cyclodextrins as enhancers of the aqueous solubility of the anthelmintic drug mebendazole: thermodynamic considerations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties